The HIV prevention pill to watch is monthly, not daily
A new oral PrEP candidate, alimatravir, is still in phase 3 trials. The public-health news is that access planning has started before the results arrive.
HIV prevention may be about to get a simpler option: one pill taken once a month. The drug is alimatravir, also called MK-8527. It is made by Merck/MSD and is being tested as PrEP, which means medicine taken by HIV-negative people to reduce the chance of getting HIV.
UNAIDS said on 5 August that alimatravir is in promising phase 3 trials and could add another prevention tool if the trials succeed. The word “if” matters. This is not an approved drug, and it is not proof that a monthly pill prevents HIV. Phase 3 is the large human-trial stage that must show safety and efficacy, meaning that the drug works for its intended use.
Why this matters now
The usual pattern in global health is slow: a drug proves itself, rich markets get it first, and low-income countries wait while price, supply, licensing, and regulation catch up. Merck is trying to do part of that work early. Its access plan includes voluntary generic licenses covering 129 low- and middle-income countries, plus named manufacturers in India, Kenya, South Africa, and Uganda.
That does not solve delivery. It does change the clock. If alimatravir works, public agencies and clinics could have generic supply plans, local manufacturing partners, and demand forecasts ready sooner. UNAIDS is pushing the same point: science only matters if the product reaches people quickly and at a price health systems can pay.
The practical gain
Daily PrEP already works when people can get it and take it. But daily medicine can collide with stigma, storage, travel, privacy, routine, and cost. Injectable PrEP helps some people, but shots require clinic visits and cold-chain logistics. A monthly oral pill would sit between those models: less frequent than daily tablets, easier to distribute than an injection program.
PrEPWatch says two phase 3 trials are testing alimatravir against daily oral PrEP. One trial enrolls about 4,580 cisgender women in Kenya, South Africa, and Uganda. The other enrolls about 4,390 participants across 16 countries, including men who have sex with men, transgender people, and gender non-binary people. The listed end dates run into 2027.
What can go wrong
The first risk is simple: the drug may fail, or it may work less well than hoped in one group. The second risk is access. A license can exist on paper while clinics still lack money, test kits, staff, community trust, or approval from national regulators. The third risk is overclaiming. A monthly pill would not replace condoms, testing, treatment, or local prevention programs; it would add one more option.
The good read is narrow. Alimatravir is not a victory yet. It is a serious candidate with unusually early access planning, and that planning is the part worth watching this month.